Tesamorelin
Tesamorelin is an FDA-approved synthetic GHRH analog used to treat excess abdominal fat in HIV-infected patients. It reduces visceral adipose tissue and improves metabolic markers.
Protocol
1–2 mg subcutaneous daily
Half-Life
25–38 minutes
Molecular Structure & Chemistry
44 residues • 711 atoms • Skeletal Formula
C215H357N71O67S
4,248.06 g/mol
5037.645 Da
10.78
+4
-0.8
Amino Acid Sequence
Biological Mechanisms
Visceral fat reduction
Observed in clinical research as a primary mechanism of action for Tesamorelin.
Improved lipid profile
Observed in clinical research as a primary mechanism of action for Tesamorelin.
Increased GH and IGF-1
Observed in clinical research as a primary mechanism of action for Tesamorelin.
Cognitive improvement in older adults
Observed in clinical research as a primary mechanism of action for Tesamorelin.
Lean mass preservation
Observed in clinical research as a primary mechanism of action for Tesamorelin.
Safety & Risk Analysis
Critical Safety Warning
Black market peptides can be contaminated, mislabeled, or dangerous. Only obtain peptides via a registered doctor and legitimate pharmacy. Never attempt self-administration without professional medical supervision.
Community Journey Log
Log Your Journey
Share your research observations with the community.
Sign in to contribute
Create a free account to log your research journey and share observations with the community.
Community Observations (0)
No journey logs yet. Be the first to share.
This compound is for research purposes only. Clinical applications must be directed by a licensed physician.
View Community Logs